—Dr Cantekin has responded to virtually none of the substance of our article, but instead advances invalid accusations and other misleading statements.First, as for "special oversight," the OSI noted that "the recommendations concerning operations of the OMRC were not intended as sanctions..." but "were intended to provide safeguards against even the appearance of possible conflict of interest..."1(p3) The OSI did not find that Dr Bluestone had "financial ties to drug companies." Dr Bluestone had received research support from drug companies and honoraria for presentations at scientific and educational meetings, but the OSI did not find that these funds were "undisclosed." The OSI also did not find "bias."2Second, the OSI commentary on antibiotic therapy now cited by Cantekin referred not to our New England Journal of Medicine article3 that Cantekin and his coauthors had criticized4 and that our JAMA article defended, but rather
Mandel EM, Rockette HE, Bluestone CD, Paradise JL, Nozza RJ. Antimicrobial Therapy for Otitis Media With Effusion: The Pittsburgh Response-Reply. JAMA. 1993;270(4):450. doi:10.1001/jama.1993.03510040053017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: